1. Scrip
  2. >>Business
  3. >>Legal & IP

IRA Updates: Lawsuit Filers Push For Fast Decisions, ICER Plans Cost Analyses

 
• By Jessica Merrill

Merck & Co. requested a swift summary judgment in the Medicare drug price negotiation case it filed in Washington, DC, while the US Chamber of Commerce filed for a preliminary injunction.

court gaval
New motions were filed in two lawsuits against the IRA • Source: Shutterstock

Merck & Co., Inc. is pushing for a fast court decision in a lawsuit it earlier filed against the US government over the implementation of a new Medicare drug price negotiation program, authorized by the Inflation Reduction Act (IRA). With just weeks to go until the US Centers for Medicare & Medicaid Services reaches key deadlines for the implementation of the program, Merck, in an 11 July court filing, urged a district court to make a summary judgement in the case.

Merck was the first plaintiff to file a lawsuit against the IRA, with legal action taken in Washington, DC, district...

More from Legal & IP

More from Business

2030’s Top Therapies: Incretin Agonists Loom Large

 
• By Edwin Elmhirst

Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By Vibha Ravi

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump ups pressure on MFN pricing; Pfizer says pharma working with Trump on direct sales; Sanofi says direct sales worth considering: Aurigene Oncology CEO on biotech valuations and more; and Novartis progresses pipeline-in-a-product assets.